Reaction

Polymyalgia Rheumatica reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,075 reports · 80 co-occurring drugs

As of the last recalculation, Polymyalgia Rheumatica appears in 3,075 FAERS reports alongside 80 co-occurring drug terms. The strongest observed disproportionality signal is SARILUMAB (PRR 53.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Sarilumab	196	53.6	54.0
Diltiazem Hydrochloride Extended-Release Tablets	34	20.4	20.5
Alendronate Sodium	209	15.0	15.0
Mometasone	38	14.2	14.2
Risedronate Sodium	58	12.9	12.9
Pembrolizumab	177	12.0	12.0
Efavirenz	18	11.0	11.0
Theophylline Anhydrous	20	11.0	11.0
Theophylline	18	10.7	10.7
Rabeprazole	31	9.6	9.6
Diltiazem Hydrochloride	48	9.5	9.5
Mepolizumab	67	9.3	9.3
Ipilimumab	56	8.9	8.9
Atezolizumab	50	8.8	8.9
Prednisone	540	8.6	8.6
Metformin Hydrochloride Tablets	71	8.6	8.6
Metformin Hydrochloride Extended-Release Tablets	71	8.6	8.6
Metformin Hydrochloride Tablet	71	8.6	8.6
Metformin Hydrochloride	71	8.3	8.3
Alendronate Sodium Tablet	22	8.1	8.1
Atorvastatin Calcium, Film Coated	81	8.0	8.0
Nivolumab	107	7.7	7.7
Omalizumab	94	7.7	7.7
Romosozumab-Aqqg	15	7.5	7.5
Mometasone Furoate	44	7.2	7.2
Pitavastatin Calcium	10	6.6	6.6
Cephalexin	21	6.6	6.6
Telmisartan	17	6.5	6.5
Tapentadol Hydrochloride	31	6.3	6.3
Zoledronic Acid	37	6.3	6.3
Oxybutynin Chloride	8	6.2	6.2
Tiotropium Bromide Inhalation Spray	10	6.1	6.1
Rosuvastatin Calcium	25	6.0	6.1
Dutasteride	7	5.8	5.8
Atorvastatin Calcium	196	5.7	5.7
Ranibizumab	22	5.6	5.6
Zinc	20	5.5	5.5
Amlodipine Besylate And Valsartan	9	5.5	5.5
Zinc Chloride	20	5.5	5.5
Zinc Gluconate	21	5.5	5.5
Prednisolone	139	5.4	5.4
Prednisolone Oral	139	5.4	5.4
Prednisolone Oral Solution	139	5.4	5.4
Indapamide	14	5.3	5.3
Methimazole	6	5.2	5.2
Ezetimibe	56	5.1	5.1
Durvalumab	15	5.0	5.0
Desoximetasone	14	5.0	5.0
Rabeprazole Sodium	20	5.0	5.0
Ezetimibe And Simvastatin	11	4.9	4.9
Irbesartan	32	4.9	4.9
Rosuvastatin	141	4.8	4.8
Piperacillin And Tazobactam	9	4.8	4.8
Tocilizumab	78	4.7	4.7
Piperacillin Sodium,Tazobactam Sodium	18	4.6	4.6
Pemetrexed	14	4.4	4.4
Raloxifene Hydrochloride	9	4.2	4.2
Denosumab	118	4.1	4.1
Bicalutamide	9	4.0	4.0
Rivastigmine	11	4.0	4.0
Budesonide And Formoterol Fumarate Dihydrate	56	4.0	4.0
Pemetrexed Disodium	20	3.6	3.6
Alirocumab	13	3.5	3.5
Polatuzumab Vedotin	5	3.5	3.5
Nilotinib	15	3.5	3.5
Benralizumab	10	3.4	3.4
Inclisiran	4	3.4	3.4
Nintedanib	15	3.2	3.2
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	3.2	3.2
Bendamustine Hcl	7	3.1	3.1
Teriparatide	45	2.7	2.7
Abiraterone	5	2.5	2.5
Axitinib	6	2.1	2.1
Encorafenib	3	2.1	2.1
Ravulizumab	4	2.0	2.0
Lenvatinib	9	1.9	1.9
Emicizumab	3	1.6	1.6
Evolocumab	36	1.5	1.5
Bimekizumab	4	1.3	1.3
Dupilumab	72	1.0	1.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.